- Home
- AMRX vs HCM Comparison
AMRX vs HCM Comparison
Compare AMRX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRX
- HCM
- Stock Information
- Founded
- AMRX 2002
- HCM 2000
- Country
- AMRX United States
- HCM Hong Kong
- Employees
- AMRX N/A
- HCM N/A
- Industry
- AMRX Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- AMRX Health Care
- HCM Health Care
- Exchange
- AMRX Nasdaq
- HCM Nasdaq
- Market Cap
- AMRX 2.3B
- HCM 2.5B
- IPO Year
- AMRX N/A
- HCM N/A
- Fundamental
- Price
- AMRX $7.32
- HCM $13.89
- Analyst Decision
- AMRX Strong Buy
- HCM Hold
- Analyst Count
- AMRX 4
- HCM 1
- Target Price
- AMRX $11.50
- HCM $19.00
- AVG Volume (30 Days)
- AMRX 1.9M
- HCM 62.8K
- Earning Date
- AMRX 05-02-2025
- HCM 03-19-2025
- Dividend Yield
- AMRX N/A
- HCM N/A
- EPS Growth
- AMRX N/A
- HCM N/A
- EPS
- AMRX N/A
- HCM 0.04
- Revenue
- AMRX $2,830,186,000.00
- HCM $630,201,000.00
- Revenue This Year
- AMRX $10.20
- HCM $14.86
- Revenue Next Year
- AMRX $7.15
- HCM $19.54
- P/E Ratio
- AMRX N/A
- HCM $63.21
- Revenue Growth
- AMRX 13.42
- HCM N/A
- 52 Week Low
- AMRX $6.29
- HCM $11.51
- 52 Week High
- AMRX $9.48
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- AMRX 46.61
- HCM 50.07
- Support Level
- AMRX $7.02
- HCM $13.13
- Resistance Level
- AMRX $7.39
- HCM $13.66
- Average True Range (ATR)
- AMRX 0.18
- HCM 0.36
- MACD
- AMRX -0.00
- HCM 0.05
- Stochastic Oscillator
- AMRX 45.80
- HCM 81.25
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.